Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Ozempic (semaglutide) and Trulicity (dulaglutide) are prescription drugs used for people with type 2 diabetes and certain other conditions. Both drugs are injected under the skin. Ozempic and ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

Since starting Ozempic ®, in addition to eating healthier ... type 2 diabetes have an increased risk of developing chronic kidney disease and are more likely to experience a major cardiovascular ...